Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Mixed Phenotype Acute Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Mixed Phenotype Acute Leukemia

Interventions

DRUG: Dasatinib
DRUG: Methotrexate
DRUG: Prednisone
BIOLOGICAL: Rituximab
DRUG: Venetoclax
BIOLOGICAL: Blinatumomab
PROCEDURE: Bone Marrow Aspiration and Biopsy
PROCEDURE: Lumbar Puncture
PROCEDURE: Biospecimen Collection

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]